This page is specifically intended to support patients who have been prescribed Aimovig (erenumab) by a UK healthcare provider. If you have any questions about your medication, ask your doctor, nurse or pharmacist and read the patient information leaflet provided with your medicine.

 

 

 

More information about Aimovig

Summary of product characteristics (SPC) for Aimovig
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Patient information leaflet (PIL) for Aimovig
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

 

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See yellowcard.mhra.gov.uk for how to report side effects.

AIM20-C027b October 2020.
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You should also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.